But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
ApexOnco Front Page
Recent articles
Persevera is a bust, but Roche hasn’t given up on the front line.
Shortly after ponsegromab, visugromab is to start phase 2/3.
Progress with three bispecific molecules is rewarded with a $120m equity raise.
Meanwhile, ASK Pharm challenges Hutchmed in cMet.
Keynote-D18 might have failed on a technicality, but now cash is running out.
ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
